INCY - Incyte Corporation
| Previous Close | 114.27 |
| Open | 113.74 |
| Bid | 112.00 x 100 |
| Ask | 120.00 x 100 |
| Day's Range | 112.71 - 114.39 |
| 52 Week Range | 83.01 - 153.15 |
| Volume | 1,571,603 |
| Avg. Volume | 1,536,160 |
| Market Cap | 24.05B |
| Beta | 1.48 |
| PE Ratio (TTM) | -144.18 |
| EPS (TTM) | -0.79 |
| Earnings Date | Oct 31, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 148.61 |
- Market Realist•yesterday
Gilead Sciences Stock: Performance in 3Q17
Gilead Sciences stock has risen ~15.2% in 3Q17 and 13.9% year-to-date as of October 20, 2017.
Markit•2 days agoSee what the IHS Markit Score report has to say about Incyte Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Bloomberg•5 days ago
Incyte Might Win a Cancer-Drug Battle But Lose the War
Even if its suit over alleged IP theft succeeds, the competition is already fierce.
- Capital Cube•5 days ago
ETFs with exposure to Incyte Corp. : October 16, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- Investor's Business Daily•5 days ago
6 Top Biotech Companies In Innovation Earn Recognition In New Awards
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
- Investor's Business Daily•5 days ago
Incyte Cancer Treatment Uses Patients' Immune System To Fight Disease
Incyte stands out among biotech companies chasing next-generation treatments that work with patients' own immune systems to combat cancer.
- Business Wire•9 days ago
Incyte to Report Third Quarter Financial Results
Incyte Corporation announced today that it has scheduled its third quarter financial results conference call and webcast for 10:00 a.m. ET on Tuesday, October 31, 2017.
- Forbes•11 days ago
One Of Biotech's Hottest Names Embraces Pharma's Bygone Era
Incyte has one cancer blockbuster, and it's got Wall Street banking on another. Its secret: embracing an older age of pharma.
- American City Business Journals•15 days ago
Take a look: Incyte unveils new global headquarters in Wilmington
While one may expect to have to go to a local park to find a walking trail, community gardens, putting green and a pickleball court side by side, employees of Incyte Corp. will find all those outdoor amenities at the biopharmaceutical company's new global headquarters in Wilmington. Incyte CEO Herve Hoppenot said the expansion was needed to provide more space for the company's growing research and development activities.
- Business Wire•15 days ago
Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware
Incyte Corporation and Cancer Support Community Delaware today announced the establishment of the Incyte Cancer Care Assistance Fund for Delaware which will provide emergency financial assistance for cancer patients, their caregivers and family members living in Delaware.
- Capital Cube•16 days ago
ETFs with exposure to Incyte Corp. : October 5, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- Forbes•17 days ago
Cancer-Cure Makers Make Great Takeover Stocks
This company's impressive technology portfolio make it a great acquisition candidate.
Motley Fool•23 days ago3 Stocks That Turned $7,000 Into $130,200
There have been some big winners over the past decade, but few have surpassed Priceline Group, Regeneron Pharmaceuticals, and Incyte.
- Zacks•23 days ago
Agenus (AGEN) Remains Focused on Drug Development Programs
Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.
Markit•24 days agoSee what the IHS Markit Score report has to say about Incyte Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding INCY totaled $8.79 billion.
- Investopedia•26 days ago
12 Stocks That Will Push the S&P 500 Higher
Goldman Sachs says sales growth will be the key ingredient driving stocks higher
- Capital Cube•26 days ago
ETFs with exposure to Incyte Corp. : September 25, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- Zacks•26 days ago
Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite
Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite
- Motley Fool•27 days ago
3 Monster Biotech Stocks in the Making
They've got successful drugs. They're profitable. All these biotechs need to become huge is a little luck and time.
Markit•last monthSee what the IHS Markit Score report has to say about Incyte Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Motley Fool•last month
3 Small-Cap Biotech Stocks to Buy This Fall
Why small-cap biotechs Celldex Therapeutics, Idera Pharmaceuticals, and NewLink Genetics could be big winners.
- GlobeNewswire•last month
Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress
UTRECHT, The Netherlands, Sept. 19, 2017-- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the second ...
- GlobeNewswire•last month
Incyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell
What: Incyte Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, will visit the Nasdaq MarketSite in Times Square. In honor ...
- Zacks•last month
Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.
- Reuters•last month
Lilly/Incyte pill beats placebo in mid-stage eczema trial
Eli Lilly and Co and Incyte Corp on Thursday said a mid-stage trial of their oral drug baricitinib showed that at the highest dose it worked better than placebo for people with moderate-to-severe atopic dermatitis. The finding could be a boost for the drug's prospects, which suffered a setback earlier this year after U.S. regulators turned down an application for its use in rheumatoid arthritis, saying that more data was needed. Baricitinib, in a class of drugs known as Jak inhibitors, is sold in the European Union under the brand name Olumiant for treating rheumatoid arthritis.
